ADARx Pharmaceuticals, Inc.
ADRX Nasdaq
SEC CIK 1802369
Follow ADARx Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$2.2M
+42.6% vs same quarter last year
Net income
−$28.1M
−57.2% vs same quarter last year
EPS, diluted
−$1.74
+5.9% vs same quarter last year
Operating income
−$32.2M
−39.9% vs same quarter last year
Source: SEC XBRL filings · latest filing